Related Experiment Video

Updated: May 6, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.7K

Type 1 diabetes and cardiovascular disease

Oliver Schnell1, Francesco Cappuccio, Stefano Genovese

  • 1Forschergruppe Diabetes e,V,, Helmholtz Center Munich, Ingolstaedter Landstrasse 1, 85764 Munich-Neuherberg, Germany. Oliver.Schnell@lrz.uni-muenchen.de.

Cardiovascular Diabetology
|October 30, 2013
PubMed

Insights

Intensive insulin therapy significantly reduces cardiovascular complications in Type 1 diabetes, as shown by the DCCT/EDIC study. This approach is crucial for improving life expectancy and managing diabetes-related heart issues.

Area of Science:

  • Endocrinology
  • Cardiology
  • Metabolic Diseases

Background:

  • Cardiovascular disease (CVD) significantly reduces life expectancy in Type 1 diabetes.
  • Hyperglycemia-induced oxidative stress is a primary driver of micro- and macrovascular complications.
  • Coronary calcifications, cardiac autonomic neuropathy, and hypoglycemia contribute to cardiac abnormalities in Type 1 diabetes.

Purpose of the Study:

  • To review the impact of intensive insulin therapy on cardiovascular complications in Type 1 diabetes.
  • To discuss the pathophysiological mechanisms linking Type 1 diabetes to CVD.
  • To explore emerging therapeutic strategies, including GLP-1-based treatments.

Main Methods:

  • Review of findings from the Diabetes Control and Complications Trial (DCCT) and its follow-up, Epidemiology of Diabetes Interventions and Complications (EDIC).
  • Analysis of pathophysiological factors contributing to CVD in Type 1 diabetes.
  • Evaluation of pilot studies on glucagon-like peptide (GLP)-based therapies.

Main Results:

  • Intensive insulin therapy demonstrably reduces the incidence and progression of both micro- and macrovascular complications.
  • The DCCT/EDIC study established the concept of metabolic memory, highlighting long-term benefits of glycemic control.
  • Pilot studies suggest GLP-1 analogues can decrease insulin requirements.

Conclusions:

  • Intensified insulin therapy is the established standard of care for Type 1 diabetes, significantly improving cardiovascular outcomes.
  • Understanding the role of oxidative stress, neuropathy, and hypoglycemia is key to managing CVD risk.
  • GLP-1-based therapies represent a promising future direction for managing Type 1 diabetes and its cardiovascular sequelae.

More Related Videos

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

25.3K
Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells06:27

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Published on: May 6, 2013

16.3K

Related Concept Videos

Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1...
89
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular...
122
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.5K
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
57
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.0K
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
45